UNSPSC 51323204: Pirinixil

This classification denotes an anti-lipidemic agent with the molecular formula C16H19ClN4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 969LVT6GJ2, chemically known as 2-((4-chloro-6-(2,3-xylidino)-2-pyrimidinyl)thio)-n-(2-hydroxyethyl)acetamide but generally known as pirinixil, which bears US NIH Compound Identifier 68851. European Medicines Agency schedules Pirinixil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09916MIG.

UNSPSC 51323204 Pirinixil is a Commodity code encompassing pharmaceutical supply procurement by state and local government entities. The recent solicitation activity under this code shows state and local governments sourcing emergency medical medications, generic pharmaceuticals, and over-the-counter products through direct manufacturer relationships and cooperative purchasing agreements. The City of Tampa's procurement of Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) for fire rescue operations exemplifies the acute-care medication demand; the Texas Health and Human Services Commission's Therapeutic Pharmacy Initiative RFI and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic pharmaceuticals RFP illustrate the broader state-level demand for cost-managed supply chains serving health plans, employee groups, and health care facilities. Issuing bodies include municipal fire departments and purchasing offices, state health and human services commissions, and state-administered cooperative purchasing alliances operating across multiple state members. Vendors responding to these opportunities must meet FDA compliance, Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) requirements, and comprehensive insurance obligations including commercial general liability coverage.

Recent activity concentrates in Florida, Texas, and Minnesota, with MMCAP's multistate model extending purchasing reach to participating jurisdictions including Oregon. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications with a response deadline of April 8, 2026, an estimated contract value of $40,000, and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount; the contract carries a one-year initial term with options to renew for two additional one-year periods. The Texas HHS Commission posted RFI HHS0017013 on March 27, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs operating outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendor participation through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and a two-year contract term effective July 1, 2026, with evaluation weighting of 75 percent on price competitiveness and 25 percent distributed across administrative compliance, EDI capability, and pricing formats.